Bicara Therapeutics Inc. (BCAX)
| Market Cap | 1.16B +16.0% |
| Revenue (ttm) | n/a |
| Net Income | -185.36M |
| EPS | -3.11 |
| Shares Out | 66.17M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 865,419 |
| Open | 16.92 |
| Previous Close | 16.78 |
| Day's Range | 16.60 - 17.60 |
| 52-Week Range | 13.70 - 30.99 |
| Beta | -0.69 |
| Analysts | Strong Buy |
| Price Target | 35.50 (+103.21%) |
| Est. Earnings | Nov 9, 2026 |
About BCAX
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for BCAX stock is "Strong Buy." The 12-month stock price target is $35.5, which is an increase of 103.21% from the latest price.
News
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients wi...
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients w...
BMO starts Bicara at Outperform, sees meaningful upside potential
BMO Capital initiated coverage of Bicara Therapeutics (BCAX) with an Outperform rating and $35 price target The firm sees an attractive setup around Bicara’s lead cancer therapy ficerafusp alfa, addin...
Bicara Therapeutics initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of Bicara Therapeutics (BCAX) with an Outperform rating and $35 price target BMO rolled out coverage on nine biotechnology companies, saying each might be considered a…
Bicara Therapeutics price target lowered to $34 from $35 at BofA
BofA lowered the firm’s price target on Bicara Therapeutics (BCAX) to $34 from $35 and keeps a Buy rating on the shares. The firm, which updated its model following the…
Bicara Therapeutics price target raised to $20 from $18 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Bicara Therapeutics (BCAX) to $20 from $18 and keeps a Neutral rating on the shares. Bicara reported Q2 results with an 82c…
Bicara Therapeutics price target raised to $39 from $28 at BTIG
BTIG raised the firm’s price target on Bicara Therapeutics (BCAX) to $39 from $28 and keeps a Buy rating on the shares after its Q2 results and management change announcements.
Bicara Therapeutics price target raised to $20 from $18 at Mizuho
Mizuho raised the firm’s price target on Bicara Therapeutics (BCAX) to $20 from $18 and keeps a Neutral rating on the shares following the Q2 report.
Bicara Therapeutics price target raised to $33 from $30 at Wedbush
Wedbush raised the firm’s price target on Bicara Therapeutics (BCAX) to $33 from $30 and keeps an Outperform rating on the shares after the company reported Q2 earnings and provided…
Bicara Therapeutics price target raised to $39 from $37 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Bicara Therapeutics (BCAX) to $39 from $37 and keeps an Overweight rating on the shares.
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients wi...
Bicara Therapeutics Earnings Call Transcript: Q2 2026
Leadership transitions position the company for commercialization as FICERA advances in pivotal trials, with strong clinical data showing improved survival in head and neck cancer. Operating expenses rose with expanded clinical and commercial activities, and cash runway extends into 2029.
Bicara Therapeutics Earnings release: Q2 2026
Bicara Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Bicara Therapeutics Slides: Q2 2026
Bicara Therapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 11, 2026.
Bicara Therapeutics Quarterly report: Q2 2026
Bicara Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
Bicara CEO Claire Mazumdar to switch roles, Ryan Cohlhepp to succeed
Bicara Therapeutics (BCAX) announced strategic leadership transitions. Ryan Cohlhepp, Bicara’s president and COO will succeed Claire Mazumdar as CEO effective January 1, 2027. As part of this planned ...
Bicara Therapeutics reports Q2 EPS (82c), consensus (83c)
“This transition marks a natural evolution for Bicara as we maintain strong enrollment momentum that enables a clear line of sight to a topline interim analysis which we believe will…
Bicara Therapeutics Slides: Corporate presentation
Bicara Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients wi...
Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
BOSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients wi...
Bicara Therapeutics Transcript: Study update
Ficera demonstrated robust, durable efficacy in first-line HPV-negative head and neck cancer, doubling three-year overall survival versus standard of care and achieving deep responses in most patients. Safety was manageable, and biomarker data confirmed the mechanism of action, supporting ongoing pivotal trials.
Bicara Therapeutics Press release: Study update
Bicara Therapeutics issued a press release on May 22, 2026, disclosing material business information to investors.
Bicara Therapeutics Slides: Study update
Bicara Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 22, 2026.
Bicara Therapeutics management to meet with Cantor
Meeting to be held in New York on May 26 hosted by Cantor.
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrosp...